Dementia is the leading cause of death in the UK, having a huge impact on people living with the condition, their families and the health systems supporting them. We hear from Dementia UK’s Andrew Pike, Head of Policy, Campaigns and Public Affairs, about how the UK Government can help to alleviate these pressures, most notably through aiding specialist nursing support.
Sepsis causes 350,000 adult deaths annually in the US alone. Sepsis Alliance focuses on raising awareness, improving education, and advocating for life-saving policies. Senior Clinical Content Advisor Marijke Vroomen Durning discusses the risk factors and best prevention methods to help in avoiding sepsis.
Despite the significant disease burden, Myalgic encephalomyelitis (ME), previously known as chronic fatigue syndrome (CFS), lacks effective diagnostics and therapeutics. Emily Taylor, President and CEO of Solve M.E., explains why dedicated research for Infection-Associated Chronic Conditions and Illnesses (IACCIs) such as ME/CFS is vitally needed.
A study that was reported on in the Lancet Neurology showed that over 3 billion people worldwide are living with neurological conditions, making these disorders the leading cause of illness and disability globally.
Jules Knight, Consultant Admiral Nurse for Young Onset Dementia at Dementia UK, tells us about the prevalence of young onset dementia and some of the challenges that people living with dementia can face.
Regular foot check-ups are critical for mitigating foot problems in people with diabetes; Lorna Rothery spoke to the podiatry team at Mid Yorkshire Teaching Hospital about the risk factors for and prevention of diabetic foot problems.
A second groundbreaking drug for Alzheimer's disease has been rejected for widespread use by the NHS in England; according to the drugs spending watchdog, the drug known as Donanemab does not offer sufficient value for money.
A recent study, published in the journal Nature looked into the six-month impact of switching neovascular age-related macular degeneration and diabetic macular oedema patients to faricimab instead of anti-VEGF therapy.
Dhivya Venkat, CEO & Co-Founder of Esya Inc., discusses the urgent need for integrating innovative diagnostics and therapies into the NHS in order to improve dementia care and diagnosis.
Consuming caffeine may have a positive impact on heart health, particularly for patients with inflammatory rheumatic diseases like lupus and rheumatoid arthritis.
Researchers at University College London (UCL) have developed a miniature scanner that could transform the way doctors diagnose and manage diseases such as cancer, diabetes, and arthritis.
Lorna Rothery interviewed Dr Lauren Sorce, PhD, RN, CPNP-AC/PC, FCCM, President of the Society of Critical Care Medicine and Co-chair of the Surviving Sepsis Campaign, to discuss the challenges of diagnosing and treating sepsis.
According to the World Health Organization (WHO), dementia is the third leading cause of mortality in Europe and the seventh globally, with a societal cost in Europe estimated to be €392bn in 2019. By 2025, 9.1 million people will be living with dementia in the European Union, rising to 14.3 million in 2050. We discuss dementia care provision with Alzheimer Europe.
Cambridge Vision Technology utilises AI-based technology to detect Alzheimer’s disease early on by using ocular biomarkers. They emphasise the importance of early detection of dementia to improve clinical outcomes for disease therapies and to maximise the economic and societal impact of this innovative new technology.
